Genomenon Logo 2021 - stacked tag (2)

Genomenon’s AI-driven Genomic Landscapes deliver a profound understanding of the genetic drivers and clinical attributes of any genetic disease, from neurodegenerative and rare diseases to cancer. This data enables Pharma to accelerate target discovery, identify genetic biomarkers for better clinical trial stratification, and develop CDx for regulatory approval.

Team Members


Mike Klein

Chief Executive Officer


Mark Kiel, MD, PhD

Founder & Chief Scientific Officer


Dave Anstey

Vice President of Sales & Business Development


Erin MacCullum

Director of Sales, Pharmaceutical and Biotech